TALS Talaris Therapeutics, Inc.

Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.

$13.04  -0.44 (-3.26%)
As of 11/26/2021 13:00:01 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  05/07/2021
Outstanding shares:  41,354,643
Average volume:  75,078
Market cap:   $557,460,588
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    87410C104
ISIN:        US87410C1045
Sedol:      BN2S6Y8
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   2.08
PS ratio:   0.00
Return on equity:   -15.79%
Net income %:   0.00%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy